MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

NVP-BAW2881

CAS No. : 861875-60-7

MCE 站：NVP-BAW2881

产品活性：NVP-BAW2881 (BAW2881) 是有效，选择性的 VEGFR2 抑制剂，IC₅₀ 为值9 nM。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：VEGFR

In Vitro: The VEGF-driven cellular receptor autophosphorylation in CHO cells of BAW2881 is inhibited with an IC₅₀ of 4 nM. BAW2881 inhibits a limited number of kinases including c-RAF, B-RAF, RET, ABL, and TIE-2 at sub-μM IC₅₀s. NVP-BAW2881 is highly selective for VEGFR, although it also demonstrates activity against Tie2 (IC₅₀=650 nM) and RET (IC₅₀=410 nM). The IC₅₀ values of NVP-BAW2881 toward a wide panel of other kinases are >10 μM. NVP-BAW2881 inhibits VEGF-A-induced phosphorylation of VEGFR-2 in HUVECs and in VEGFR-2-transfected Chinese hamster ovary cells, with IC₅₀ values of 2.9 and 4.2 nM, respectively.

In Vivo: In a transgenic mouse model of psoriasis, NVP-BAW2881 reduces the number of blood and lymphatic vessels and infiltrating leukocytes in the skin, and normalized the epidermal architecture. NVP-BAW2881 also displays strong anti-inflammatory effects in models of acute inflammation; pretreatment with topical NVP-BAW2881 significantly inhibits VEGF-A-induced vascular permeability in the skin of pigs and mice.

相关产品：Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Endocrinology Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Bevacizumab  |  Sunitinib  |  Semaxinib  |  SU 5402  |  PD173074  |  5Z-7-Oxozeaenol  |  Cediranib  |  SAR131675  |  Gandotinib  |  GW806742X  |  Tanshi IIA  |  PF-03814735  |  Vatalanib dihydrochloride  |  CP-547632  |  AST 487  |  Tyrphostin A9  |  Ki20227  |  Motesanib  |  SU14813  |  Ramucirumab  |  SU1498  |  MAZ51  |  PP121  |  Ki8751  |  ZM 306416  |  ZM323881 hydrochloride

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。